← Compound index
COMPOUND RECORD / SVETINORM

SvetinormСветинорм

An animal liver peptide mixture investigated in a Russian institute report on symptoms and liver enzyme levels.

Source linked

What the studies found

Comparison in people · 2013

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis

Study of multiple preparations

Total cholesterol
7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4.Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable.
VLDL cholesterol
1.22 ± 0.06, 0.92 ± 0.07 and 0.87 ± 0.05 mmol/L, respectively. Shared baseline 1.42 ± 0.07.Both adjunctive groups are marked significant versus standard care.
Reported fatigue
64.0%, 32.3% and 12.9%, respectively. Shared baseline 75.6%.Only the four-product group is marked significant versus standard care in the fatigue row.

The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Study notes · methods, sources and limitations

Participants or model 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.

Design Moscow, December 2011 to June 2012. Standard treatment alone (514), with Ventfort and Cerluten (319), or with those two plus Svetinorm and Endoluten (416). The Russian methods list two oral capsules each per day for three months for Ventfort, Cerluten and Svetinorm when assigned. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified.

Important limitations

  • The authors excluded statin users and people with prior stroke. The comparison provides no individual estimates for Svetinorm or Endoluten. Both editions name Svetinorm in the four-product group and outcome tables. The English dosing list instead says Suprefort. The schedule below follows the Russian methods. The table gives one shared pretreatment column. Methods of allocation and masking, timing of the reported tables and adverse-event ascertainment are unspecified. Table 1 repeats the triglyceride heading with values of unclear identity. The cholesterol, VLDL and first triglyceride rows are legible. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
  • The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. Symptom assessment and statistical methods are incompletely reported. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides. · Conference report · company reproduction

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Comparison in people · 2006

Svetinorm: clinical report on a tissue-derived preparation

Bilirubin
20.1 ± 0.8 µmol/L with Svetinorm and 23.6 ± 1.4 µmol/L with conventional care. Shared baseline 27.1 ± 1.2 µmol/L.
ALT in the report’s stated units
43.5 ± 3.5 with Svetinorm and 46.1 ± 3.8 with conventional care. Shared baseline 52.5 ± 4.1. Both arms were marked significant versus baseline.

Bilirubin was 20.1 µmol/L after adjunctive Svetinorm and 23.6 µmol/L after conventional care. The table marks a change from the shared baseline of 27.1 µmol/L.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.

Design 47 adults received Svetinorm plus usual care and 38 controls received usual care. The group methods describe two capsules twice daily before meals for 15–20 days.

Important limitations

  • A within-group change is not proof of superiority over controls. Mixed diagnoses, co-treatments and incomplete allocation reporting limit interpretation. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
  • The table gives a shared baseline and reports significance against baseline.

Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date · Institute report — commercial reproduction

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗
01 / OVERVIEW

About Svetinorm

Identity / background source ↗

Research background

Svetinorm is a liver-derived peptide preparation. A Medical Center report compared symptoms and liver blood tests during adjunctive care.

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.

Study methods

Small comparative institute report; allocation, blinding and outcome interpretation require caution

Independent replication

Independent replication not established in this collection

Source access

Report reproduction linked; source language and review scope shown per record

Safety evidence

Short-term reports do not establish long-term safety or equivalence to current products

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2013

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis

The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Study notes and original source
2013Human comparative studyRussian-language source

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis

Oral vascular, brain, liver and pineal polypeptide preparations added to standard therapy · Conference report · company reproduction

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.

The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Results and tables

Reported findings and study design

Moscow, December 2011 to June 2012. Standard treatment alone (514), with Ventfort and Cerluten (319), or with those two plus Svetinorm and Endoluten (416). The Russian methods list two oral capsules each per day for three months for Ventfort, Cerluten and Svetinorm when assigned. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified.

Population or model 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.

Results · Russian conference reproduction, pp. 8–10, and matching English edition
MeasureResultComparison, timing and statistics
Total cholesterol7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4.Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable.
VLDL cholesterol1.22 ± 0.06, 0.92 ± 0.07 and 0.87 ± 0.05 mmol/L, respectively. Shared baseline 1.42 ± 0.07.Both adjunctive groups are marked significant versus standard care.
Reported fatigue64.0%, 32.3% and 12.9%, respectively. Shared baseline 75.6%.Only the four-product group is marked significant versus standard care in the fatigue row.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. Symptom assessment and statistical methods are incompletely reported. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
Source reviewed
Authors’ conference material, Russian reproduction, PDF pages 8–10, methods and Tables 1–2. English and Russian editions describe the same comparison.
Study limitations
  • The authors excluded statin users and people with prior stroke. The comparison provides no individual estimates for Svetinorm or Endoluten.
  • Both editions name Svetinorm in the four-product group and outcome tables. The English dosing list instead says Suprefort. The schedule below follows the Russian methods.
  • The table gives one shared pretreatment column. Methods of allocation and masking, timing of the reported tables and adverse-event ascertainment are unspecified.
  • Table 1 repeats the triglyceride heading with values of unclear identity. The cholesterol, VLDL and first triglyceride rows are legible.
  • The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Reviewed 2026-11-16.

Read the source ↗

Comparison in people · 2006

Svetinorm: clinical report on a tissue-derived preparation

Bilirubin was 20.1 µmol/L after adjunctive Svetinorm and 23.6 µmol/L after conventional care. The table marks a change from the shared baseline of 27.1 µmol/L.

Bilirubin · 20.1 ± 0.8 µmol/L with Svetinorm and 23.6 ± 1.4 µmol/L with conventional care. Shared baseline 27.1 ± 1.2 µmol/L.

Study notes and original source
2006Human comparative studyRussian-language source

Svetinorm: clinical report on a tissue-derived preparation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date

Bilirubin was 20.1 µmol/L after adjunctive Svetinorm and 23.6 µmol/L after conventional care. The table marks a change from the shared baseline of 27.1 µmol/L.

Results and tables

Reported findings and study design

47 adults received Svetinorm plus usual care and 38 controls received usual care. The group methods describe two capsules twice daily before meals for 15–20 days.

Population or model 85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.

Results · Medical Center report, clinical characteristics and liver chemistry table
MeasureResultComparison, timing and statistics
Bilirubin20.1 ± 0.8 µmol/L with Svetinorm and 23.6 ± 1.4 µmol/L with conventional care. Shared baseline 27.1 ± 1.2 µmol/L.
ALT in the report’s stated units43.5 ± 3.5 with Svetinorm and 46.1 ± 3.8 with conventional care. Shared baseline 52.5 ± 4.1. Both arms were marked significant versus baseline.

The table gives a shared baseline and reports significance against baseline.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.
Source reviewed
Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
  • A within-group change is not proof of superiority over controls. Mixed diagnoses, co-treatments and incomplete allocation reporting limit interpretation.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Reviewed 2026-11-16.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗